On Thursday (08/21), the National Health Surveillance Agency (Anvisa) will hold the webinar "Construction of the 2026-2027 Regulatory Agenda: Preliminary list of topics notice".

The meeting aims to present to society the main elements of the Regulatory Agenda (RA) 2026-2027, as well as to guide on submitting contributions to the preliminary list of topics.

The webinar is a virtual seminar that seeks to strengthen Anvisa's transparency initiatives, offering updated content to the public. The broadcast will be conducted online, with real-time interaction through a chat.

What is Anvisa's Regulatory Agenda?

The Regulatory Agenda is a planning tool that defines the agency's priorities for a certain period, usually biennial. It guides the topics that will be subject to regulation, norm review, and inspection, ensuring predictability and transparency in Anvisa's actions.

The agenda's construction is participatory, involving civil society and regulated sectors, with the aim of aligning the agency's actions with the needs of the population and the market.

Cannabis in the 2024-2025 Agenda

In the Regulatory Agenda 2024-2025, theme 2.28 in the "Medicines" category proposed the review of the regulation of cannabis products for medicinal purposes (RDC nº 327/2019). The goal was to enable safe access to essential health products and services.

In March 2025, Anvisa addressed the topic present in the Agenda by approving a draft of Public Consultation to update RDC 327/2019, which defines the requirements for the manufacture, import, and commercialization of cannabis-based products in Brazil.

The public consultation ran until June 2 and received 1,476 contributions, including proposed changes, opinions, and suggestions from society. The collected information should support adjustments to the final proposal text, which will be submitted for deliberation by Anvisa's Collegiate Board of Directors (Dicol).